SCHEMBL4617971

SCHEMBL4617971

COC(=O)C(C)(C)NS(=O)(=O)c1cc(S(=O)(=O)c2ccccc2)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
ALDH1A1 P00352 3/20 0.45
POLB P06746 1/20 0.45
THRB P10828 2/20 0.44
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
SLC12A2 P55011 1/20 0.43
SLC12A5 Q9H2X9 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
SLC16A1 P53985 1/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
GLA P06280 1/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 2/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636847 0.89 LMNA (0.47) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL4618233 0.80 LMNA (0.48) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL15890427 0.78 GAA (0.57) LMNAALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL4636851 0.77 ALDH1A1 (0.43) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL9658929 0.72 LMNA (0.61) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL4616119 0.72 LMNA (0.57) LMNAALDH1A1POLBSMN1; SMN2SLC12A2
SCHEMBL4617963 0.72 LMNA (0.47) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL4617968 0.72 LMNA (0.53) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL4618655 0.71 LMNA (0.56) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL4618473 0.71 LMNA (0.49) LMNAALDH1A1POLBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 LMNA 4608/4885ALDH1A1 1865/4885POLB 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.